On July 1, 2026 Valerio Therapeutics (FR0010095596 – ALVIO), a biotechnology company pioneering next-generation precision-guided RNA therapeutics ("Valerio" or the "Company"), reported that it has signed a binding offer for the acquisition of 100% of the share capital of etherna immunotherapies NV ("etherna") (the "Acquisition").

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

etherna is a leading technology platform company pioneering the development of mRNA and lipid nanoparticle (LNP) technologies, including manufacturing up to GMP. With over a decade of expertise, etherna has built an integrated suite of proprietary technologies, including customizable lipid nanoparticles (cLNPs) and advanced mRNA chemistry, enabling the development and delivery of differentiated RNA therapeutics.

The Creation of a Global Leader in Targeted RNA Medicines
The Acquisition marks a major milestone in Valerio’s strategy to become a global leader in targeted nucleic acid medicines. By uniting three complementary technology platforms – nucleic acid chemistry, LNP delivery and targeted moiety engineering – within a fully integrated biotech supported by in-house manufacturing capabilities, the Acquisition positions Valerio to accelerate the development of next-generation RNA medicines targeting cells beyond the liver.

The Acquisition combines Valerio’s proprietary sdAb-targeting and conjugation technologies with Etherna’s mRNA and LNP capabilities. Together, these technologies enable targeted delivery of nucleic acid payloads to specific cell types and tissues, while in-house GMP manufacturing and CMC capabilities address a key bottleneck many nucleic acid companies face when scaling programs into the clinic.

The Acquisition would create a fully integrated RNA medicines company with a proprietary pipeline and the capabilities to discover, develop and manufacture its own product candidates, with the ambition to advance at least two programs in immunological indications through IND-enabling studies and into the clinic within 18 to 24 months. The lead program demonstrates the potential of the combined platform, focused on the development of an in vivo CAR-T approach to target and modulate pathological B- and T cells in immunological diseases. Furthermore, the company aims to unlock substantial partnership, co-development, and licensing opportunities with major pharmaceutical companies seeking to extend nucleic acid medicines beyond the liver and into a broader spectrum of tissues and indications, while continuing to support existing collaborations and partnerships through its manufacturing capabilities.

Today’s announcement follows the appointment of Gilles Besin as Chief Executive Officer. Dr. Besin brings more than 20 years of experience in drug discovery, immunology, and RNA-based medicine, and has played a key role in building and scaling several biotechnology companies. Most recently, he served as Chief Scientific Officer at Orbital Therapeutics, an in vivo CAR‑T company that leveraged targeted LNP technology and was acquired by BMS in 2025. Following the acquisition, he led BMS’s RNA and in vivo CAR‑T programs. Earlier in his career, he held senior leadership roles at Affinivax, playing a key role in the acquisition by GSK, and Moderna.

"The acquisition of Etherna is a transformative moment for Valerio, propelling us toward our vision of building a fully integrated RNA therapeutics company. By bringing together Etherna’s cutting-edge science with our proprietary targeted delivery technologies, we are creating a powerful engine for innovation. Together, these capabilities position us to efficiently and confidently advance the next generation of RNA medicines beyond the liver, opening new therapeutic frontiers and expanding what is possible for patients worldwide." said Gilles Besin, Ph.D., CEO of Valerio.

"This transaction represents a natural next step in Etherna’s mission to unlock the full potential of nucleic acid-based medicines. Together with Valerio, we will have the scientific capabilities, leadership and ambition to translate these technologies into a growing pipeline of targeted medicines, building long-term value while advancing novel therapies for patients – while continuing to support our partners in discovery, development and manufacturing." said Bernard Sagaert, CEO of etherna.

Terms and Conditions of the Acquisition
The acquisition of 100% of the share capital and voting rights of etherna is contemplated for a total enterprise value of €30 million, subject to customary adjustments.
The Acquisition would be settled through a mix of:
(i) a cash consideration, fully backed by committed financing from Valerio’s existing shareholders; and
(ii) a share consideration consisting of contribution in kind of etherna shares (the "Contributions") to the Company.

The Acquisition is supported by leading life sciences investors, with key etherna shareholders becoming Valerio shareholders as part of the transaction, reflecting confidence in the strategic vision and value creation.
Completion of the Acquisition remains subject to (i) applicable regulatory approvals in the relevant jurisdictions, including foreign direct investment control, (ii) finalizing of the transaction documentation (iii) completion of a financing pursuant to outstanding shareholders’ resolutions, fully secured by subscription undertakings from Valerio’s existing shareholders up to the cash consideration, and (iv) the approval by Valerio’s shareholders of the Contributions at an extraordinary general meeting to be convened for that purpose, secured by voting undertakings from shareholders representing more than 70% of the voting rights, whose decision shall be based in particular on a report by a contributions auditor assessing the fairness of the contribution transaction.
The parties have entered a 6-week exclusivity period to finalize the definitive transaction documentation required in the context of the contemplated Acquisition, in accordance with the provisions of the binding offer.

The binding offer has received the unanimous approval of etherna’s board of directors.

Advisors
Van Lanschot Kempen NV is serving as exclusive financial advisor to Valerio Therapeutics with Goodwin Procter LLP serving as legal counsel.
Moelis & Company is serving as financial advisor to etherna with Deloitte serving as legal counsel.

(Press release, eTheRNA, JUL 1, 2026, View Source [SID1234669034])

On July 1, 2026 Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a U.S. biopharmaceutical company, reported the closing on an agreement with subsidiary of Apotex Health Corp. ("Apotex"), the largest Canadian-based pharmaceutical company, to integrate their branded U.S. businesses. Under the terms of the agreement, Apotex has acquired Cumberland’s line of branded pharmaceuticals for cash consideration of $100 million funded at closing, which followed approval by Cumberland’s shareholders.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased to complete this value-creating transaction, which was strongly supported by our shareholders with over 99% of the votes cast in favor of the transaction," said A.J. Kazimi, CEO of Cumberland. "This milestone significantly strengthens our financial position, enabling us to focus on the large market opportunities associated with our pipeline programs. Our goals are to deliver innovative new products to improve patient care, while continuing to build value for our shareholders."

Cumberland has retained its robust portfolio of innovative product candidates and its majority ownership position in Cumberland Emerging Technologies Inc. Following the closing, Cumberland will focus its resources on developing ifetroban, a potent thromboxane antagonist currently being studied across clinical programs targeting serious rare and progressive diseases:

· Duchenne Muscular Dystrophy Cardiomyopathy:
Cumberland announced breakthrough results in a Phase II clinical study of ifetroban in patients with cardiomyopathy associated with this rare, fatal genetic neuromuscular disease. Interactions with the FDA have been underway regarding study results and requirements for approval. The program has received FDA Orphan Drug, Rare Pediatric Disease and Fast Track designations.

· Systemic Sclerosis:
Cumberland has conducted a Phase II clinical study evaluating the safety of ifetroban in patients with this debilitating autoimmune disorder. Evaluation of the study data is underway with top-line results anticipated as the next milestone.

· Idiopathic Pulmonary Fibrosis:
A Phase II study evaluating ifetroban in patients with the most common form of progressive fibrosing interstitial lung disease is actively enrolling at medical centers across the U.S.. Favorable interim safety findings have been announced and the next milestone is the announcement of the efficacy results.

· Cancer Metastasis:
Cumberland, in collaboration with Vanderbilt Health, recently announced the results of a Pilot Study of ifetroban in patients with high-risk solid tumors. The findings suggests the potential to block cancer metastasis, as a favorable trend was identified with fewer deaths due to metastatic disease in those receiving ifetroban rather than a placebo. The Phase 2 clinical trial also found ifetroban to be safe and well tolerated in the oncology patients, supporting further development of the drug to prevent cancer metastasis.

(Press release, Cumberland Pharmaceuticals, JUL 1, 2026, View Source [SID1234669033])

On July 1, 2026 Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, reported that its Phase 2a study evaluating Namodenoson in patients with advanced pancreatic ductal adenocarcinoma achieved its primary safety endpoint and demonstrated durable overall survival outcomes.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The open-label Phase IIa study enrolled 20 patients with advanced pancreatic ductal adenocarcinoma who had progressed following standard therapies. Fourteen patients received Namodenoson as third-line treatment, five as second-line treatment, and one as fourth-line treatment. Namodenoson was well tolerated, with a safety profile consistent with prior clinical trials.

Following extended follow-up, an updated survival analysis was performed in the third-line population, focusing on the eight patients who survived at least two months after treatment initiation, thereby excluding patients with rapidly progressive disease unlikely to derive benefit from systemic therapy.

Among the eight evaluable third-line patients:

● Median overall survival exceeded 5 months

● 62.5% of patients survived five months or longer

● 37.5% survived seven months or longer

● Two patients remain alive at the data cutoff, including one patient continuing treatment and another followed for almost nine months

● Durable disease control was observed, including progression-free survival extending beyond seven months.

The findings identify a subset of heavily pretreated pancreatic cancer patients achieving prolonged survival despite receiving Namodenoson as third-line therapy, supporting further clinical development of Namodenoson.

Notably, among the five patients treated in the second-line setting, one patient remains alive more than 18 months after initiation of Namodenoson therapy, representing the longest survivor in the study.

Prof. Salomon Stemmer, who is leading the Phase 2a study and is an oncology key opinion leader and Professor at the Davidoff Institute of Oncology, Rabin Medical Center, Israel, commented: "Pancreatic cancer remains one of the most difficult malignancies to treat, particularly after failure of standard therapies. The results of Namodenoson monotherapy are impressive and the favorable safety profile together with the prolonged survival observed in a subgroup of patients, suggest biological activity worthy of further investigation. Based on these findings and the growing preclinical evidence demonstrating enhancement of chemotherapy activity, I believe the next logical step is evaluation of Namodenoson in combination with chemotherapy."

Based on these findings and discussions with the study’s principal investigator, Can-Fite plans to advance Namodenoson into a Phase 2b combination study with chemotherapy. The decision follows recently published peer-reviewed preclinical data demonstrating that Namodenoson (2-Cl-IB-MECA) enhances the anti-tumor activity of chemotherapeutic agents in pancreatic cancer models by simultaneously inhibiting multiple tumor proliferation and drug-resistance pathways, including Wnt/β-catenin and Hedgehog signalling, while reducing expression of multidrug-resistance proteins. The publication further demonstrated that Namodenoson increased chemosensitivity in pancreatic cancer cells, providing a strong mechanistic rationale for combination therapy

About Namodenoson

Namodenoson is a small orally bioavailable drug that binds with high affinity and selectivity to the A3 adenosine receptor (A3AR). Namodenoson is currently being evaluated in a pivotal Phase 3 trial for advanced liver cancer, concluded successfully a Phase 2a study in pancreatic cancer and is enrolling patients in a Phase 2b trial for the treatment of Metabolic Dysfunction-associated Steatohepatitis (MASH). A3AR is highly expressed in diseased cells whereas low expression is found in normal cells. This differential expression may be one of the important factors that accounts for the excellent safety profile of the drug.

(Press release, Can-Fite BioPharma, JUL 1, 2026, View Source [SID1234669032])

On July 1, 2026 AB Science S.A. (the "Company" or "AB Science", Euronext – FR0010557264 – AB) reported the successful completion of a capital increase of a total gross amount of EUR 2.3 million subscribed by a limited number of investors (the "Private Placement").

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Private Placement is not subject to a prospectus requiring an approval from the French Financial Market Authority (Autorité des Marchés Financiers – the "AMF").

Use of proceeds

The Company intends to use the net proceeds of the Private Placement to finance research and development programs of the Company, the priority being the AB8939 program in acute myeloid leukemia and the masitinib in amyotrophic lateral sclerosis.

This transaction strengthens the Company’s cash position and enables it to cover its financing needs beyond the next 12 months.

Terms and conditions of the Private Placement

The Private Placement, for a total amount of EUR 2.3 million (including share issue premium), was carried out through the issuance, without preferential subscription rights and without a priority subscription period, of 3,475,758 new ordinary shares of the Company (the "New Shares"), each with one share warrant attached (a "BSA" and, together with the New Share to which it is attached, an "ABSA"). One BSA entitle their holder to subscribe to one new ordinary share of the Company at a price of EUR 0.93 per ordinary share. The issuance of the ABSA was conducted through a share capital increase with cancellation of shareholders’ preferential subscription rights for the benefit of investors within the category of persons defined by the 15th resolution of the Combined General Meeting of the Company’s shareholders of June 30, 2026 (the "General Meeting"), in accordance with article L. 225-138 of the French commercial code (the "Private Placement").

The issue of the ABSAs, representing approximately 4.54% of the Company’s share capital, on a non-diluted basis, before completion of the Private Placement, and 4.34% of the Company’s share capital, on a non-diluted basis, after completion of the Private Placement, was decided on June 30, 2026 by the Chief Executive Officer, pursuant to the delegation of competence granted to him by the board of directors dated June 30, 2026, pursuant to the delegation of competence granted to it under the 15th resolution of the General Meeting.

The issue price of one ABSA is EUR 0.66 (including share issue premium), representing a facial discount of 24.23% (i.e. EUR 0.2110) to the volume-weighted average price of the AB Science shares on the regulated market of Euronext Paris ("Euronext Paris") over the three trading days preceding the setting of such issue price, i.e. June 26, 29 and 30, 2026, i.e. EUR 0.8710 (the "3-day VWAP").

The issue price of an ABSA, including the theoretical value of the BSA attached to it (as described below, together with the issue price of the new ordinary share issued upon exercise of one BSA) represents a total 24.56% discount per AB Science share to the 3-day VWAP, consistent with the maximum discount authorized by the General Meeting pursuant to its 15th resolution.

Terms and conditions of the BSA

One BSA is attached to each New Share.

One BSA entitle their holder to subscribe to one new ordinary share of the Company at a price of EUR 0.93 per ordinary share.

The BSAs may be exercised at any time within 60 months of their issuance. In the event all BSAs are exercised, a total number of 3,475,758 additional ordinary shares of the Company will be issued, representing additional total proceeds of approximately EUR 3.2 million.

The theoretical value of each BSA, assuming a volatility of 32.088%1 and based on closing price as of June 30, 2026, is equal to EUR 0.2758 using Black & Scholes model.

The BSAs will be immediately detached (détachés) from the New Shares upon issuance and will not be listed.

Impact of the Private Placement on the Company’s shareholding

Following the issuance of the ABSAs, the Company’s total share capital will be EUR 800,296.65 (and EUR 835,054.23 in the event of exercise of all BSAs). It will be comprised of 73,251,991 ordinary shares (and of 76,727,749 ordinary shares in the event of exercise of all BSAs) with a par value of EUR 0.01. There will be no change on the number of preferred shares.

To the Company’s knowledge, immediately prior to completion of the Private Placement and after completion of the Private Placement, the breakdown of the Company’s share capital is as follows:

Before the capital increase After the capital increase (before exercising the BSA) After the capital increase and exercise of the BSA
Number of shares ( 1) % Diluted base ( 2) Number of shares ( 1) % Diluted base ( 2) Number of shares ( 1) % Diluted base ( 2)
A. Moussy 6 782 434 8,86% 15,41% 6 782 434 8,47% 14,90% 6 782 434 8,12% 14,42%
AMY SAS (3) 12 273 000 16,03% 12,12% 12 273 000 15,34% 11,72% 12 273 000 14,70% 11,34%
Subtotal concert A. Moussy 19 055 434 24,89% 27,54% 19 055 434 23,81% 26,62% 19 055 434 22,82% 25,77%
Other investors members of the concert 2 432 777 3,18% 5,27% 2 432 777 3,04% 5,09% 2 432 777 2,91% 4,93%
Actions in the pact 1 128 497 1,47% 3,98% 1 128 497 1,41% 3,85% 1 128 497 1,35% 3,72%
Actions outside the pact 1 304 280 1,70% 1,29% 1 304 280 1,63% 1,25% 1 304 280 1,56% 1,21%
Total concert 21 488 211 28,07% 32,80% 21 488 211 26,85% 31,71% 21 488 211 25,73% 30,69%
Other investors above 5% 6 888 610 9,00% 7,96% 6 888 610 8,61% 7,69% 6 888 610 8,25% 7,45%
Other investors 48 177 086 62,93% 59,24% 51 652 844 64,54% 60,59% 55 128 602 66,02% 61,86%
Total 76 553 907 100,00% 100,00% 80 029 665 100,00% 100,00% 83 505 423 100,00% 100,00%
(1) All classes of shares are affected. The number of ordinary shares amounts to 69,776,233 before the Private Placement, 73,251,991 after the Private Placement (but before exercise of the BSAs), and 76,727,749 after the Private Placement and exercise of the BSAs.
(2) The diluted basis takes into account the exercise of all instruments giving access to the capital, the definitive allocation of all free shares and the conversion of all preferred shares into ordinary shares (aiming for the highest theoretical dilution).
(3) AMY SAS is a company controlled by A. Moussy.

On the basis of the share capital of the Company immediately after completion of the Private Placement, the interest of a shareholder who held 1.00% of the Company’s share capital prior to the above-mentioned capital increase and who did not subscribe to it now stands at 0.9566% on a non-diluted basis and 0.7309% on a diluted basis.

Admission to trading of the New Shares

The New Shares are expected to be admitted to trading on the regulated market of Euronext Paris on July 6, 2026.

The New Shares will be subject to the provisions of the Company’s by-laws and will be assimilated to existing shares upon final completion of the Private Placement. They will bear current dividend rights and will be admitted to trading on the same listing line as the Company’s existing shares under the same ISIN code FR0010557264 – AB.

The BSAs will not be admitted to trading on any market.

The new ordinary shares issued upon exercise of the BSAs will be, when issued, subject to the provisions of the Company’s by-laws and will be assimilated to existing shares. They will bear current dividend rights and will be admitted to trading on the same listing line as the Company’s existing shares under the same ISIN code FR0010557264 – AB.

Lock-up commitments

The Company has signed a lock-up commitment (to the benefit of the investors) pursuant to which it has agreed to a lock-up period of 45 calendar days from the date of the settlement and delivery of the Private Placement, subject to certain customary exceptions.

The directors and officers of the Company have signed a lock-up commitment (to the benefit of the investors) pursuant to which they have agreed to a lock-up period of 90 calendar days from the date of the settlement and delivery of the Private Placement, subject to certain customary exceptions.

Financial Intermediaries

Maxim Group LLC acted as the sole placement agent in connection with the Private Placement.

Indicative timetable

June 30, 2026 Decisions of the Board of Directors deciding the principle of the Private Placement.
June 30, 2026 Decisions of the Chief Executive Officer setting the terms and conditions of the Private Placement (including the subscription price of the ABSAs and the gross amount of the Private Placement).
July 1st, 2026 Publication of this press release.

July 3, 2026 Settlement-delivery of the ABSAs – Detachment of the BSA

July 6, 2026 Start of trading of the New Shares on Euronext Paris.
Risk factors

AB Science draws the attention of the public to the risk factors relating to the Company and its business described in its annual management reports and press releases, which are available free of charge on the Company’s website (www.ab-science.com).

In addition, the main risks specific to securities are as follows:

The existing shareholders who do not participate in the Private Placement will see their shareholding in the share capital of AB Science diluted, and this shareholding may also be diluted in the event of exercise of the BSA, as well as in the event of new securities transactions.

The volatility and liquidity of AB Science shares could fluctuate significantly. The market price of the Company’s shares may fluctuate and fall below the subscription price of the shares issued in the context of the Private Placement. The sale of Company shares may occur on the secondary market, after the Private Placement, and have a negative impact on the Company share price.

About masitinib

Masitinib is a novel oral tyrosine kinase inhibitor that is being developed to target mast cells and macrophages, key immune cells, through inhibition of a limited number of kinases. Due to its unique mode of action, the Company believed that masitinib can be developed in a wide range of diseases, including oncology, inflammatory diseases, and certain central nervous system diseases. In oncology, through its immunotherapy activity, masitinib may have an effect on survival, alone or in combination with chemotherapy. Through its activity on mast cells and microglial cells and therefore its inhibitory effect on the activation of the inflammatory process, masitinib may have an effect on the symptoms associated with certain inflammatory and central nervous system diseases.

About AB8939

AB8939 is a new synthetic microtubule-destabilizing drug candidate. Preclinical data suggests that AB8939 has broad anticancer activity, with a notable advantage over standard chemotherapies that target microtubules of being able to overcome P-glycoprotein (Pgp) and myeloperoxidase (MPO) mediated drug resistance. Development of drug resistance often restricts the clinical efficacy of microtubule-targeting chemotherapy drugs (for example, taxanes and vinca alkaloids); thus, AB8939 has the potential to be developed in numerous oncology indications.

(Press release, AB Science, JUL 1, 2026, View Source [SID1234669031])

On July 1, 2026 Imugene Limited (ASX: IMU), a clinical-stage immunooncology company, reported additional patient data from the concurrent BTK inhibitor (BTKi) cohort of its ongoing Phase 1b basket study of azer-cel (azercabtagene zapreleucel).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This Mantle Cell Lymphoma (MCL) patient, the first MCL patient treated in the azer-cel Phase 1b study, had previously failed BTKi therapy and achieved a complete response at the Day 28 assessment.

MCL is an aggressive B-cell non-Hodgkin lymphoma that typically presents at an advanced stage and remains incurable with standard therapies. BTK inhibitors have become an established treatment across relapsed or refractory MCL, but a significant proportion of patients develop resistance or intolerance over time, leaving them with limited remaining options.

All patients enrolled in the concurrent BTKi cohort have relapsed on or are refractory to BTKi therapy, a standard treatment across multiple B-cell malignancies. Despite the established efficacy of BTK inhibitors, a significant proportion of patients develop resistance over time and are left with limited remaining options. This cohort evaluates whether concurrent dosing of azer-cel with a BTKi may restore or enhance therapeutic activity in this setting. The global BTKi market reached approximately US$12.0 billion in 2025.

Leslie Chong, Managing Director and CEO of Imugene, said, "Achieving a second complete response in the concurrent BTKi cohort, including in the first Mantle Cell Lymphoma patient treated in the study, further reinforces our belief in azer-cel’s potential for patients who have progressed on BTKi therapy. Given the broad use of BTK inhibitors across B-cell malignancies and the limited treatment options available following progression, we believe this concurrent dosing approach represents a highly promising clinical and commercial opportunity for azer-cel."

To date, four patients have been dosed in the azer-cel Phase 1b concurrent BTKi cohort, two of which are evaluable, both achieving a complete response. Further updates will be provided as additional data becomes available, and the dataset matures.

Azer-cel is an off-the-shelf, allogeneic CAR T cell therapy which targets CD19 to treat blood cancers. Azer-cel is derived from healthy donor T cells and ready for administration within days, without the three-to-six-week manufacturing lead time required for autologous CAR T products.

About the Phase 1b azer-cel trial

The azer-cel allogeneic CAR T trial is an ongoing, open-label, multi-centre Phase 1b clinical trial in the U.S. and Australia, for CAR T relapsed patients and CAR T naïve patients diagnosed with a broad range of Non-Hodgkins lymphomas including follicular lymphoma (FL), chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL), marginal zone lymphoma (MZL), Waldenstrom macroglobulinemia (WM), and mantle cell lymphoma (MCL). The trial has most recently expanded into a concurrent BTKi cohort, for patients with a range of B-cell malignancies who have previously failed BTKi therapy. Treatment with azer-cel, lymphodepletion and IL-2 has produced meaningful clinical responses across multiple indications, including multiple complete responses in the concurrent BTKi cohort. Additionally, the safety profile is manageable and generally well tolerated.

(Press release, Imugene, JUL 1, 2026, View Source [SID1234669019])